Leerink Partnrs increased their FY2024 earnings per share estimates for Werewolf Therapeutics in a report released on Monday, ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Amazon said it is introducing low, upfront pricing for a clinical visit, treatment plan, and free medication delivery for ...

Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical ...

Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on VYGR stock, giving a Buy rating yesterday.

On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive ...

Leerink Partners, a leading investment bank specializing in healthcare, announced today the addition of Grant Curry and Jason Truman to its biopharma M&A team. Both have joined Leerink as Senior ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

In the preceding three months, 4 analysts have released ratings for 4D Molecular Therapeutics FDMT, presenting a wide array ...